Human cytolytic fusion proteins (hCFPs) are comprised of a specific cell-surface-binding moiety and an effector molecule of human origin. In contrast to common immunotoxins, including bacterial or plant toxins, they are considered not to be immunogenic. Two examples for human pro-apoptotic effector proteins are the serine protease Granzyme B and the RNase Angiogenin. Pre-clinical testing of functionality in in vitro and in vivo studies is essential for therapeutics. Establishing relevant animal models that have predictive value for therapeutic success is a great challenge in biomedical research. In this study, we investigated the species-dependent cytotoxic activity of two hCFPs prior to their application in a murine inflammation model. We found that in vitro and ex vivo either hCFP was able to kill human cells only, leaving murine cells unaffected. In contrast, no species-dependency was found for the bacterial Pseudomonas exotoxin A based immunotoxin H22(scFv)-ETA’. This species-dependent functioning has to be carefully considered when performing pre-clinical studies in animal models.
References
[1]
Kreitman, R.J. Recombinant toxins for the treatment of cancer. Curr. Opin. Mol. Ther. 2003, 5, 44–51.
[2]
Allen, T.M. Ligand-targeted therapeutics in anticancer therapy. Nat. Rev. Cancer 2002, 2, 750–763, doi:10.1038/nrc903.
[3]
Cawley, D.B.; Herschman, H.R.; Gilliland, D.G.; Collier, R.J. Epidermal growth factor-toxin A chain conjugates: EGF-ricin A is a potent toxin while EGF-diphtheria fragment A is nontoxic. Cell 1980, 22, 563–570, doi:10.1016/0092-8674(80)90366-9.
[4]
Williams, D.P.; Parker, K.; Bacha, P.; Bishai, W.; Borowski, M.; Genbauffe, F.; Strom, T.B.; Murphy, J.R. Diphtheria toxin receptor binding domain substitution with interleukin-2: Genetic construction and properties of a diphtheria toxin-related interleukin-2 fusion protein. Protein Eng. 1987, 1, 493–498, doi:10.1093/protein/1.6.493.
[5]
Zhou, X.X.; Ji, F.; Zhao, J.L.; Cheng, L.F.; Xu, C.F. Anti-cancer activity of anti-p185HER-2 ricin A chain immunotoxin on gastric cancer cells. J. Gastroenterol. Hepatol. 2010, 25, 1266–1275, doi:10.1111/j.1440-1746.2010.06287.x.
[6]
Hu, C.C.; Ji, H.M.; Chen, S.L.; Zhang, H.W.; Wang, B.Q.; Zhou, L.Y.; Zhang, Z.P.; Sun, X.L.; Chen, Z.Z.; Cai, Y.Q.; et al. Investigation of a plasmid containing a novel immunotoxin VEGF165-PE38 gene for antiangiogenic therapy in a malignant glioma model. Int. J. Cancer 2010, 127, 2222–2229, doi:10.1002/ijc.25217.
[7]
Hristodorov, D.; Mladenov, R.; Huhn, M.; Barth, S.; Thepen, T. Macrophage-targeted therapy: CD64-based immunotoxins for treatment of chronic inflammatory diseases. Toxins 2012, 4, 676–694, doi:10.3390/toxins4090676.
[8]
Barta, S.K.; Zou, Y.; Schindler, J.; Shenoy, N.; Bhagat, T.D.; Steidl, U.; Verma, A. Synergy of sequential administration of a deglycosylated ricin A chain-containing combined anti-CD19 and anti-CD22 immunotoxin (Combotox) and cytarabine in a murine model of advanced acute lymphoblastic leukemia. Leukemia Lymphoma 2012, 53, 1999–2003, doi:10.3109/10428194.2012.679267.
[9]
Schnell, R.; Vitetta, E.; Schindler, J.; Borchmann, P.; Barth, S.; Ghetie, V.; Hell, K.; Drillich, S.; Diehl, V.; Engert, A. Treatment of refractory Hodgkin's lymphoma patients with an anti-CD25 ricin A-chain immunotoxin. Leukemia 2000, 14, 129–135, doi:10.1038/sj.leu.2401626.
[10]
Pai, L.H.; Pastan, I. Clinical trials with Pseudomonas exotoxin immunotoxins. Curr. Top. Microbiol. Immunol. 1998, 234, 83–96.
[11]
Frankel, A.E.; Powell, B.L.; Hall, P.D.; Case, L.D.; Kreitman, R.J. Phase I trial of a novel diphtheria toxin/granulocyte macrophage colony-stimulating factor fusion protein (DT388GMCSF) for refractory or relapsed acute myeloid leukemia. Clin. Cancer Res. 2002, 8, 1004–1013.
[12]
Furman, R.R.; Grossbard, M.L.; Johnson, J.L.; Pecora, A.L.; Cassileth, P.A.; Jung, S.H.; Peterson, B.A.; Nadler, L.M.; Freedman, A.; Bayer, R.L.; et al. A phase III study of anti-B4-blocked ricin as adjuvant therapy post-autologous bone marrow transplant: CALGB 9254. Leukemia Lymphoma 2011, 52, 587–596.
[13]
Kreitman, R.J.; Tallman, M.S.; Robak, T.; Coutre, S.; Wilson, W.H.; Stetler-Stevenson, M.; Fitzgerald, D.J.; Lechleider, R.; Pastan, I. Phase I trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in patients with hairy cell leukemia. J. Clin. Oncol. 2012, 30, 1822–1828.
[14]
Mathew, M.; Verma, R.S. Humanized immunotoxins: A new generation of immunotoxins for targeted cancer therapy. Cancer Sci. 2009, 100, 1359–1365, doi:10.1111/j.1349-7006.2009.01192.x.
[15]
Trapani, J.A. Granzymes: A family of lymphocyte granule serine proteases. Genome Biol. 2001, 2, REVIEWS3014.
[16]
Metkar, S.S.; Wang, B.; Ebbs, M.L.; Kim, J.H.; Lee, Y.J.; Raja, S.M.; Froelich, C.J. Granzyme B activates procaspase-3 which signals a mitochondrial amplification loop for maximal apoptosis. J. Cell Biol. 2003, 160, 875–885, doi:10.1083/jcb.200210158.
[17]
Trapani, J.A.; Jans, P.; Smyth, M.J.; Froelich, C.J.; Williams, E.A.; Sutton, V.R.; Jans, D.A. Perforin-dependent nuclear entry of granzyme B precedes apoptosis, and is not a consequence of nuclear membrane dysfunction. Cell Death Differ. 1998, 5, 488–496.
[18]
Barry, M.; Heibein, J.A.; Pinkoski, M.J.; Lee, S.F.; Moyer, R.W.; Green, D.R.; Bleackley, R.C. Granzyme B short-circuits the need for caspase 8 activity during granule-mediated cytotoxic T-lymphocyte killing by directly cleaving Bid. Mol. Cell. Biol. 2000, 20, 3781–3794, doi:10.1128/MCB.20.11.3781-3794.2000.
Saxena, S.K.; Rybak, S.M.; Davey, R.T., Jr.; Youle, R.J.; Ackerman, E.J. Angiogenin is a cytotoxic, tRNA-specific ribonuclease in the RNase A superfamily. J. Biol. Chem. 1992, 267, 21982–21986.
[22]
Stahnke, B.; Thepen, T.; Stocker, M.; Rosinke, R.; Jost, E.; Fischer, R.; Tur, M.K.; Barth, S. Granzyme B-H22(scFv), a human immunotoxin targeting CD64 in acute myeloid leukemia of monocytic subtypes. Mol. Cancer Ther. 2008, 7, 2924–2932, doi:10.1158/1535-7163.MCT-08-0554.
[23]
Huhn, M.; Sasse, S.; Tur, M.K.; Matthey, B.; Schinkothe, T.; Rybak, S.M.; Barth, S.; Engert, A. Human angiogenin fused to human CD30 ligand (Ang-CD30L) exhibits specific cytotoxicity against CD30-positive lymphoma. Cancer Res. 2001, 61, 8737–8742.
[24]
Liu, Y.; Cheung, L.H.; Hittelman, W.N.; Rosenblum, M.G. Targeted delivery of human pro-apoptotic enzymes to tumor cells: In vitro studies describing a novel class of recombinant highly cytotoxic agents. Mol. Cancer Ther. 2003, 2, 1341–1350.
[25]
Zhang, L.; Zhao, J.; Wang, T.; Yu, C.J.; Jia, L.T.; Duan, Y.Y.; Yao, L.B.; Chen, S.Y.; Yang, A.G. HER2-targeting recombinant protein with truncated pseudomonas exotoxin A translocation domain efficiently kills breast cancer cells. Cancer Biol. Ther. 2008, 7, 1226–1231, doi:10.4161/cbt.7.8.6261.
[26]
Hetzel, C.; Bachran, C.; Fischer, R.; Fuchs, H.; Barth, S.; Stocker, M. Small cleavable adapters enhance the specific cytotoxicity of a humanized immunotoxin directed against CD64-positive cells. J. Immunother. 2008, 31, 370–376, doi:10.1097/CJI.0b013e31816a2d23.
[27]
Stahnke, B.; Thepen, T.; Stocker, M.; Rosinke, R.; Jost, E.; Fischer, R.; Tur, M.K.; Barth, S. Granzyme B-H22(scFv), a human immunotoxin targeting CD64 in acute myeloid leukemia of monocytic subtypes. Mol. Cancer Ther. 2008, 7, 2924–2932, doi:10.1158/1535-7163.MCT-08-0554.
[28]
Tur, M.K.; Huhn, M.; Jost, E.; Thepen, T.; Brummendorf, T.H.; Barth, S. In vivo efficacy of the recombinant anti-CD64 immunotoxin H22(scFv)-ETA' in a human acute myeloid leukemia xenograft tumor model. Int. J. Cancer 2011, 129, 1277–1282.
[29]
van Roon, J.A.; van Vuuren, A.J.; Wijngaarden, S.; Jacobs, K.M.; Bijlsma, J.W.; Lafeber, F.P.; Thepen, T.; van de Winkel, J.G. Selective elimination of synovial inflammatory macrophages in rheumatoid arthritis by an Fcgamma receptor I-directed immunotoxin. Arthrit. Rheum. 2003, 48, 1229–1238.
[30]
van Vuuren, A.J.; van Roon, J.A.; Walraven, V.; Stuij, I.; Harmsen, M.C.; McLaughlin, P.M.; van de Winkel, J.G.; Thepen, T. CD64-directed immunotoxin inhibits arthritis in a novel CD64 transgenic rat model. J. Immunol. 2006, 176, 5833–5838.
[31]
Ribbert, T.; Thepen, T.; Tur, M.K.; Fischer, R.; Huhn, M.; Barth, S. Recombinant, ETA'-based CD64 immunotoxins: improved efficacy by increased valency, both in vitro and in vivo in a chronic cutaneous inflammation model in human CD64 transgenic mice. Br. J. Dermatol. 2010, 163, 279–286, doi:10.1111/j.1365-2133.2010.09824.x.
[32]
Tur, M.K.; Huhn, M.; Thepen, T.; Stocker, M.; Krohn, R.; Vogel, S.; Jost, E.; Osieka, R.; van de Winkel, J.G.; Fischer, R.; et al. Recombinant CD64-specific single chain immunotoxin exhibits specific cytotoxicity against acute myeloid leukemia cells. Cancer Res. 2003, 63, 8414–8419.
[33]
de Poot, S.A.H.; Westgeest, M.; Hostetter, D.R.; Van Damme, P.; Plasman, K.; Demeyer, K.; Broekhuizen, R.; Gevaert, K.; Craik, C.S.; Bovenschen, N. Human and mouse granzyme M display divergent and species-specific substrate specificities. Biochem. J. 2011, 437, 431–442, doi:10.1042/BJ20110210.
[34]
Kaiserman, D.; Bird, C.H.; Sun, J.R.; Matthews, A.; Ung, K.; Whisstock, J.C.; Thompson, P.E.; Trapani, J.A.; Bird, P.I. The major human and mouse granzymes are structurally and functionally divergent. J. Cell Biol. 2006, 175, 619–630, doi:10.1083/jcb.200606073.
[35]
Cullen, S.P.; Adrain, C.; Luthi, A.U.; Duriez, P.J.; Martin, S.J. Human and murine granzyme B exhibit divergent substrate preferences. J. Cell Biol. 2007, 176, 435–44, doi:10.1083/jcb.200612025.
[36]
Bots, M.; Van Bostelen, L.; Rademaker, M.T.; Offringa, R.; Medema, J.P. Serpins prevent granzyme-induced death in a species-specific manner. Immunol. Cell Biol. 2006, 84, 79–86, doi:10.1111/j.1440-1711.2005.01417.x.
